L ista de publicaciones realizadas en colaboración con la Unidad de Investigación de la AEDV:

Publicaciones de la Unidad de Investigación de la FPSAEDV

 

Biobadaderm y Psonet:

 

  • Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellan M, Notario J, et al. J Dermatolog Treat. 2018:1-5.

 

  • Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gomez-Garcia FJ, et al. Br J Dermatol. 2018;179(4):863-871.

 

  • Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. Descalzo MA, Carretero G, Ferrandiz C, Rivera R, Dauden E, Gomez-Garcia FJ, et al. J Am Acad Dermatol. 2018;78(4):798-800.

 

  • Registries as real-world cohort studies that are useful and necessary in the pyramid of evidence. Davila-Seijo P, Descalzo MA. Br J Dermatol. 2018;178(1):300-301.

 

  • Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016. Carretero Hernandez G, Ferrandiz C, Rivera Diaz R, Dauden Tello E, de la Cueva-Dobao P, Gomez-Garcia FJ, et al. Actas Dermosifiliogr. 2018;109(7):617-623.

 

  • Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, Belinchon-Romero I, Carrascosa JM, Ferran M, et al. Br J Dermatol. 2017;176(3):797-799.

 

  • Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. Perez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, Herrera-Ceballos E, et al. J Eur Acad Dermatol Venereol. 2017;31(6):1021-1028.

 

  • Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Garcia-Doval I, Hernandez MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D, et al. Br J Dermatol. 2017;176(3):643-649.

 

  • Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. J Am Acad Dermatol. 2017;76(2):299-308 e216.

 

  • Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. Galiano Mejias S, Carretero G, Ferrandiz C, Vanaclocha F, Dauden E, Gomez-Garcia FJ, et al. Actas Dermosifiliogr. 2017;108(1):52-58.

 

  • A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature. Echeverria-Garcia B, Nuno-Gonzalez A, Dauden E, Vanaclocha F, Torrado R, Belinchon I, et al. Actas Dermosifiliogr. 2017;108(2):168-170.

 

  • Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ, et al. Acta Derm Venereol. 2017;97(4):516-518.

 

  • Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis. Davila-Seijo P, Garcia-Doval I. Actas Dermosifiliogr. 2017;108(1):3-5.

 

  • Response to the Comment by Van den Reek et al. on Drug Survival Analysis is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis. Davila-Seijo P, Garcia-Doval I. Actas Dermosifiliogr. 2017;108(7):697-698.

 

  • Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, et al. J Invest Dermatol. 2017;137(2):313-321.

 

  • Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. Belinchon I, Ramos JM, Carretero G, Ferrandiz C, Rivera R, Dauden E, et al. J Eur Acad Dermatol Venereol. 2017;31(10):1700-1708.

 

  • Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. Garcia-Doval I, Perez-Zafrilla B, Ferrandiz C, Carretero G, Dauden E, de la Cueva P, et al. J Dermatolog Treat. 2016;27(3):203-209.

 

  • Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. Davila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, et al. J Eur Acad Dermatol Venereol. 2016;30(11):1942-1950.

 

  • Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Sanz-Bueno J, Vanaclocha F, Garcia-Doval I, Torrado R, Carretero G, Dauden E, et al. Actas Dermosifiliogr. 2015;106(6):477-482.

 

  • Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ, et al. J Eur Acad Dermatol Venereol. 2015;29(5):858-864.

 

  • Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastian F, Gomez-Garcia FJ, Herrera-Ceballos E, et al. J Eur Acad Dermatol Venereol. 2015;29(1):156-163.

 

  • Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Dauden E, et al. Actas Dermosifiliogr. 2015;106(8):638-643.

 

  • Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. Carrascosa JM, Garcia-Doval I, Perez-Zafrilla B, Carretero G, Vanaclocha F, Dauden E, et al. J Dermatolog Treat. 2015;26(6):502-506.

 

  • Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Dauden E, et al. J Eur Acad Dermatol Venereol. 2014;28(7):907-914.

 

  • Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. Sanchez-Moya AI, Garcia-Doval I, Carretero G, Sanchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. J Eur Acad Dermatol Venereol. 2013;27(11):1366-1374.

 

  • Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, et al. Br J Dermatol. 2013;169(3):710-714.

 

  • Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Arch Dermatol. 2012;148(4):463-470.

 

  • [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]. Rivera R, Garcia-Doval I, Carretero G, Dauden E, Sanchez-Carazo J, Ferrandiz C, et al. Actas Dermosifiliogr. 2011;102(2):132-141.

 

Registro de cirugía de Mohs (REGESMOHS):

 

  • Description of patients excluded for Mohs surgery after pre-surgical evaluation: data from the Regesmohs Spanish registry. Ruiz-Salas V, Garces JR, Alonso-Alonso T, Rodriguez-Prieto MA, Toll-Abello A, Eusebio Murillo E, et al. Actas Dermosifiliogr. 2018;109(4):346-350.

 

  • Differences of Mohs micrographic surgery in basal cell carcinoma versus squamous cell carcinoma. Delgado Jimenez Y, Camarero-Mulas C, Sanmartin-Jimenez O, Garces JR, Rodriguez-Prieto MA, Alonso-Alonso T, et al. Int J Dermatol. 2018;57(11):1375-1381.

 

  • Mohs micrographic surgery in the elderly: comparison of tumours, surgery and first-year follow-up in patients younger and older than 80 years old in REGESMOHS. Camarero-Mulas C, Delgado Jimenez Y, Sanmartin-Jimenez O, Garces JR, Rodriguez-Prieto MA, Alonso-Alonso T, et al. J Eur Acad Dermatol Venereol. 2018;32(1):108-112.

 

  • Characterization of Surgical Procedures in the Spanish Mohs Surgery Registry (REGESMOHS) for 2013-2015. de Eusebio Murillo E, Martin Fuentes A, Ruiz-Salas V, Garces JR, Minano Medrano R, Lopez-Estebaranz JL, et al. Actas Dermosifiliogr. 2017;108(9):836-843.

 

  • Description of Patients Undergoing Mohs Surgery in Spain: Initial Report on Data From the Spanish Registry of Mohs Surgery (REGESMOHS). Ruiz-Salas V, Garces JR, Minano Medrano R, Alonso-Alonso T, Rodriguez-Prieto MA, Lopez-Estebaranz JL, et al. Actas Dermosifiliogr. 2015;106(7):562-568.

 

  • Census of Centers That Perform Mohs' Micrographic Surgery in Spain and Description of Their Activity: A Feasibility Study for the Mohs' Micrographic Surgery Registry of the Foundation of the Spanish Academy of Dermatology and Venereology. Alonso-Alonso T, Redondo-Bellon P, Sanmartin-Jimenez O, de Eusebio-Murillo E, Garcia-Doval I, Rodriguez-Prieto MA. Actas Dermosifiliogr. 2015;106(9):764-766.

 

Mapa de Investigación (MaIND):

 

  • Clinical research in dermatology: resources and activities associated with a higher scientific productivity. Molina-Leyva A, Descalzo MA, Garcia-Doval I. G Ital Dermatol Venereol.

 

  • Clinical Research in Dermatology and Venereology in Spanish Research Centers in 2005 Through 2014: Results of the MaIND Study. Molina-Leyva A, Descalzo MA, Garcia-Doval I. Actas Dermosifiliogr. 2018;109(1):52-57.

 

  • A Map of Clinical Dermatology Research Centers in Spain: Results of the MaIND Study. Molina-Leyva A, Descalzo MA, Garcia-Doval I. Actas Dermosifiliogr. 2017;108(9):830-835.

 

Revisiones sistemáticas:

 

  • Phototherapy in atopic dermatitis: a systematic review of the literature. Perez-Ferriols A, Aranegui B, Pujol-Montcusi JA, Martin-Gorgojo A, Campos-Dominguez M, Feltes RA, et al. Actas Dermosifiliogr. 2015;106(5):387-401.

 

  • A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. Hernandez-Martin A, Aranegui B, Martin-Santiago A, Garcia-Doval I. J Am Acad Dermatol. 2013;69(4):544-549 e548.

 

Libro blanco del cáncer cutáneo de la AEDV:

 

  • Leiomyosarcoma and Pleomorphic Dermal Sarcoma: Guidelines for Diagnosis and Treatment. Llombart B, Serra-Guillen C, Requena C, Alsina M, Morgado-Carrasco D, Machado I, et al. Actas Dermosifiliogr. 2019;110(1):4-11.

 

  • Kaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment. Requena C, Alsina M, Morgado-Carrasco D, Cruz J, Sanmartin O, Serra-Guillen C, et al. Actas Dermosifiliogr. 2018;109(10):878-887.

 

  • Guidelines for Diagnosis and Treatment of Cutaneous Sarcomas: Dermatofibrosarcoma Protuberans. Llombart B, Serra C, Requena C, Alsina M, Morgado-Carrasco D, Traves V, et al. Actas Dermosifiliogr. 2018;109(10):868-877.

 

  • Evaluation of Structure Indicators for Assessing Skin Cancer Quality of Care in Dermatology Departments. Kueder-Pajares T, Descalzo MA, Garcia-Doval I, Rios-Buceta L, Moreno-Ramirez D. Actas Dermosifiliogr. 2018;109(9):807-812.

 

  • Treatment of Malignant Cutaneous Adnexal Neoplasms. Bernardez C, Requena L. Actas Dermosifiliogr. 2018;109(1):6-23.

 

  • Precancerous Skin Lesions. Ferrandiz C, Malvehy J, Guillen C, Ferrandiz-Pulido C, Fernandez-Figueras M. Actas Dermosifiliogr. 2017;108(1):31-41.

 

  • Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-Garcia C, Rodriguez-Pazos L, Pastushenko I, et al. Actas Dermosifiliogr. 2016;107(4):318-328.

 

Prevalencia dermatológica en consulta ambulatoria (DIADERM):

 

  • Difficulties Coding Dermatological Disorders Using the ICD-10: The DIADERM Study. Gonzalez-Lopez G, Garcia-Doval I, Molina-Leyva A, Descalzo-Gallego MA, Taberner R, Gilaberte Y, et al. Actas Dermosifiliogr. 2018;109(10):893-899.

 

  • Referral of Patients to Dermatology and Teledermatology Consultations in Spain. DIADERM Study. Gonzalez-Lopez G, Descalzo-Gallego MA, Arias-Santiago S, Molina-Leyva A, Gilaberte Y, Fernandez-Crehuet P, et al. Actas Dermosifiliogr.

 

  • Outpatient Dermatological Diagnoses in Spain: Results From the National DIADERM Random Sampling Project. Buendia-Eisman A, Arias-Santiago S, Molina-Leyva A, Gilaberte Y, Fernandez-Crehuet P, Husein-ElAhmed H, et al. Actas Dermosifiliogr. 2018;109(5):416-423.

 

 

Publicaciones resultantes de asesorías a la UI:

 

  • Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. Tejera-Vaquerizo A, Garcia-Doval I, Llombart B, Canueto J, Martorell-Calatayud A, Descalzo-Gallego MA, et al. J Dermatol.

 

  • Author's reply to: Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study. Boada A, Tejera-Vaquerizo A, Ribero S, Puig S, Nagore E, Moreno-Ramirez D, et al. Int J Cancer. 2018;142(7):1504.

 

  • Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study. Boada A, Tejera-Vaquerizo A, Ribero S, Puig S, Moreno-Ramirez D, Descalzo-Gallego MA, et al. Int J Cancer. 2018;142(3):641-648.

 

  • The intriguing effect of delay time to sentinel lymph node biopsy on survival: a propensity score matching study on a cohort of melanoma patients. Tejera-Vaquerizo A, Descalzo-Gallego MA, Traves V, Requena C, Bolumar I, Pla A, et al. Eur J Dermatol. 2017;27(5):487-495.

 

  • Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study. Mercader-Garcia P, Pastor-Nieto MA, Garcia-Doval I, Gimenez-Arnau A, Gonzalez-Perez R, Fernandez-Redondo V, et al. Contact Dermatitis.

 

  • Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. Gonzalez-Llorente N, Del Olmo-Benito I, Munoz-Ollero N, Descalzo MA, Garcia-Doval I, Torrelo A. Pediatr Dermatol. 2017;34(5):554-558.

 

  • Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis. Esteves T, Aparicio G, Garcia-Patos V. BMC Pulm Med. 2016;16(1):165.

 

Otros proyectos:

 

  • How real are 'real-life studies' in psoriasis, and the uncertain meaning of drug persistence. Garcia-Doval I, Davila-Seijo P. Br J Dermatol. 2019;180(1):15-16.

 

  • Who likes to perform the Psoriasis Area and Severity Index? Garcia-Doval I, Albrecht J. Br J Dermatol. 2019;180(2):260-261.

 

  • Estimating the Prevalence of Psoriasis Using Electronic Health Records. Descalzo MA. Actas Dermosifiliogr.

 

  • Essentials for a successful registry: valid data, the right questions and timely execution. Garcia-Doval I, Stern RS. Br J Dermatol. 2018;179(4):805-806.

 

  • Optimizing case reports and case series: guidance on how to improve quality. Garcia-Doval I, Albrecht J, Flohr C, Batchelor J, Ingram JR, European Dermato-Epidemiology N. Br J Dermatol. 2018;178(6):1257-1262.

 

  • Teledermatology Implementation: The Importance of a Clear Objective. Garcia-Doval I. Actas Dermosifiliogr.

 

  • Clinical Research at the Heart of the Spanish Academy of Dermatology and Venereology. Descalzo MA. Actas Dermosifiliogr. 2018;109(2):99.

 

  • Methyl aminolevulinate photodynamic therapy for onychomycosis: a multicentre, randomized, controlled clinical trial. Gilaberte Y, Robres MP, Frias MP, Garcia-Doval I, Rezusta A, Aspiroz C. J Eur Acad Dermatol Venereol. 2017;31(2):347-354.

 

  • Systematic reviews: let's keep them trustworthy. Garcia-Doval I, van Zuuren EJ, Bath-Hextall F, Ingram JR. Br J Dermatol. 2017;177(4):888-889.

 

  • Big data in small diseases: the case of necrotizing soft-tissue infections. Garcia-Doval I, Nijsten T. Br J Dermatol. 2017;177(6):1468-1469.

 

  • Psoriasis, Metabolic Syndrome, and Systematic Reviews. Descalzo MA. Actas Dermosifiliogr. 2017;108(4):323.

 

  • Report from the first European Dermato-Epidemiology Network forum. Ascott A, Langan SM, Garcia-Doval I, Descalzo MA, Schmidt SAJ, Nijsten T, et al. Br J Dermatol. 2017;177(4):e168-e171.

 

  • Fragmented Health Care Delivery in Ichthyosis. Hernandez-Martin A, Davila'Seijo P, Soria de Francisco JM, Arroyo-Manzanal MI, Garcia-Doval I. Actas Dermosifiliogr. 2015;106(6):514-515.

 

  • Prioritization of therapy uncertainties in congenital ichthyosis: results from a Priority Setting Partnership. Hernandez-Martin A, Davila-Seijo P, de Lucas R, Baselga E, Redondo P, Martin-Santiago A, et al. Br J Dermatol. 2015;173(5):1280-1283.

 

  • Research unit of the Spanish Academy of Dermatology and Venerology Foundation. Garcia-Doval I. Actas Dermosifiliogr. 2015;106(5):346-349.

 

  • Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians. Davila-Seijo P, Hernandez-Martin A, Morcillo-Makow E, Rajan C, Garcia-Doval I. J Am Acad Dermatol. 2014;71(5):1008-1011.

 

  • Prevalence of dystrophic epidermolysis bullosa in Spain: a population-based study using the 3-source capture-recapture method. Evidence of a need for improvement in care. Hernandez-Martin A, Aranegui B, Escamez MJ, de Lucas R, Vicente A, Rodriguez-Diaz E, et al. Actas Dermosifiliogr. 2013;104(10):890-896.

 

  • Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders. Davila-Seijo P, Hernandez-Martin A, Morcillo-Makow E, de Lucas R, Dominguez E, Romero N, et al. Orphanet J Rare Dis. 2013;8:61.

  

  • Prevalence of autosomal recessive congenital ichthyosis: a population-based study using the capture-recapture method in Spain. Hernandez-Martin A, Garcia-Doval I, Aranegui B, de Unamuno P, Rodriguez-Pazos L, Gonzalez-Ensenat MA, et al. J Am Acad Dermatol. 2012;67(2):240-244.